Publicaciones en colaboración con investigadores/as de Hospital Universitario de Salamanca (71)

2024

  1. Cáncer de mama

    Oncología clínica (Arán Ediciones), pp. 203-226

  2. Real-world clinical scenarios during introduction of trastuzumab biosimilar for HER2-positive breast cancer in the European Union

    Future oncology (London, England), Vol. 20, Núm. 13, pp. 821-832

  3. Tratamiento Sistémico del Cáncer (I): Quimioterapia

    Oncología clínica (Arán Ediciones), pp. 73-87

  4. Tratamiento Sistémico del Cáncer (II): hormonoterapia

    Oncología clínica (Arán Ediciones), pp. 89-99

  5. Tratamiento Sistémico del Cáncer (III): inmunoterapia y terapias biológicas

    Oncología clínica (Arán Ediciones), pp. 101-116

  6. Urgencias en oncología

    Oncología clínica (Arán Ediciones), pp. 129-145

2023

  1. Impact of the 21-Gene Assay in Patients with High-Clinical Risk ER-Positive and HER2-Negative Early Breast Cancer: Results of the KARMA Dx Study

    Cancers, Vol. 15, Núm. 5

  2. Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk

    Cells, Vol. 12, Núm. 15

2022

  1. Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial

    Breast, Vol. 66, pp. 77-84

2021

  1. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study

    European Journal of Cancer, Vol. 156, pp. 70-82

  2. Value of skin tests for managing allergic hypersensitivity reactions to platinum compounds

    International Journal of Clinical Pharmacy, Vol. 43, Núm. 4, pp. 1123-1127

2020

  1. A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study

    Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 420-428

  2. Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)

    Breast, Vol. 54, pp. 286-292

  3. Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07)

    European Journal of Cancer Care, Vol. 29, Núm. 4

  4. Stromal SNAI2 is required for ERBB2 breast cancer progression

    Cancer Research, Vol. 80, Núm. 23, pp. 5216-5230

  5. The economic burden of metastatic breast cancer in Spain

    European Journal of Hospital Pharmacy , Vol. 27, Núm. 1, pp. 19-24

2019

  1. Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients

    Aging, Vol. 11, Núm. 9, pp. 2874-2888

  2. Neoadjuvant metformin added to systemic therapy decreases the proliferative capacity of residual breast cancer

    Journal of Clinical Medicine, Vol. 8, Núm. 12

  3. Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study

    Clinical Breast Cancer, Vol. 19, Núm. 2, pp. 105-112

  4. The C allele of ATM rs11212617 associates with higher pathological complete remission rate in breast cancer patients treated with neoadjuvant metformin

    Frontiers in Oncology, Vol. 9, Núm. MAR